Loading... Please wait... Loading... Please wait...
ESTIMATED
05/09/2024
05/09/2024
(AS OF MARCH 31)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$0.37 | -$0.37 | -$0.37 |
| Q2 2024 | 5 | -$0.38 | -$0.29 | -$0.35 |
| Q3 2024 | 1 | -$0.36 | -$0.36 | -$0.36 |
| Q4 2024 | 1 | -$0.34 | -$0.34 | -$0.34 |
| Q1 2025 | 2 | -$0.34 | -$0.34 | -$0.34 |
| Q2 2025 | 2 | -$0.35 | -$0.35 | -$0.35 |
| Q3 2025 | 2 | -$0.39 | -$0.39 | -$0.39 |
| Q4 2025 | 2 | -$0.44 | -$0.44 | -$0.44 |
Altimmune, Inc. last posted its earnings results on Thursday, May 9th, 2024. The company reported $-0.34 earnings per share for the quarter, topping analysts' consensus estimates of $-0.36 by $0.02. The company had revenue of 5,000 for the quarter and had revenue of 426,000 for the year. Altimmune, Inc. has generated $-2 earnings per share over the last year ($-1.66 diluted earnings per share) and currently has a price-to-earnings ratio of -5.04. Altimmune, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 8th, 2024 based on prior year's report dates.
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue | 03/29/2024 | Q1 2024 | -$0.34 | $5,000 | $5,000 | 12/29/2023 | Q4 2023 | -$0.54 | $2,143 | $37,000 | 11/07/2023 | Q3 2023 | -$0.40 | -$0.39 | 0.01 | $857 | $362,000 | 08/10/2023 | Q2 2023 | -$0.44 | -$0.32 | 0.12 | $3,000 | $6,000 | 05/11/2023 | Q1 2023 | -$0.49 | -$0.37 | 0.12 | $37,141 | $21,000 | 02/28/2023 | Q4 2022 | -$0.52 | -$0.40 | 0.12 | $28,857 | $-110,000 | 11/10/2022 | Q3 2022 | -$0.49 | -$0.48 | 0.01 | $867,833 | $2,000 | 08/11/2022 | Q2 2022 | -$0.45 | -$0.42 | 0.03 | $871,500 | $8,000 | 05/12/2022 | Q1 2022 | -$0.57 | -$0.44 | 0.13 | $32,000 | 03/15/2022 | Q4 2021 | -$0.64 | -$0.57 | 0.07 | $3.28 M | 11/09/2021 | Q3 2021 | -$0.36 | -$0.81 | -0.45 | $70,667 | $157,559 | 08/10/2021 | Q2 2021 | -$0.44 | -$0.60 | -0.16 | $1.89 M | $137,623 | 05/17/2021 | Q1 2021 | -$0.39 | -$0.38 | 0.01 | $837,516 | 02/25/2021 | Q4 2020 | -$0.84 | -$0.27 | 0.57 | $2.31 M | 11/09/2020 | Q3 2020 | -$0.92 | -$0.54 | 0.38 | $1.05 M | $2.94 M | 08/11/2020 | Q2 2020 | -$0.29 | -$0.94 | -0.65 | $1.35 M | $721,636 | 05/13/2020 | Q1 2020 | -$0.32 | -$0.26 | 0.06 | $2.21 M | 03/27/2020 | Q4 2019 | -$0.26 | -$0.27 | -0.01 | $575,801 | 11/13/2019 | Q3 2019 | -$0.19 | -$0.74 | -0.55 | $2.63 M | $643,978 | 08/13/2019 | Q2 2019 | -$0.25 | -$0.26 | -0.01 | $2.41 M | $1.63 M |
|---|
A. Altimmune, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 8th, 2024 based off last year's report dates.
A. In the previous quarter, Altimmune, Inc. (NASDAQ:ALT) reported $-0.34 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.36 by $0.02.
A. The conference call for Altimmune, Inc.'s latest earnings report can be listened to online.
A. The conference call transcript for Altimmune, Inc.'s latest earnings report can be read online.
A. Altimmune, Inc. (NASDAQ:ALT) has a recorded annual revenue of $426,000.
A. Altimmune, Inc. (NASDAQ:ALT) has a recorded net income of $426,000. Altimmune, Inc. has generated $-1.66 earnings per share over the last four quarters.
A. Altimmune, Inc. (NASDAQ:ALT) has a price-to-earnings ratio of -5.04 and price/earnings-to-growth ratio is -0.61.
